ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

7 links0 made here, not in the record15 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.govReplaced, or read an older version
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT04612751Phase 1b Study of Dato-DXdin Combination WithImmunotherapy With orWithout Carboplatin inAdvanced or MetastaticNon-Small Cell Lung CancerAstraZenecaPhase 1 · active not recruitinRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Oct 27 · ClinicalTrials.gov record · Version of 2026-10-27Version of 2026-10-27CONDITIONSCarcinoma, Non-Small-Cell L…The registry's MeSH filing›Nov 14 · Rule based · Finest filed termAs of now · Rule based · Main conditionMain conditionDRUGSDatopotamab deruxtecanIntervention entry›Nov 3 · Claude Opus 5.5 · BackgroundNov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · BackgroundTestedDurvalumabIntervention entry›Nov 3 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundCarboplatinIntervention entry›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedRilvegostomigEntry “AZD2936”, read by our name rule›Nov 3 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundVolrustomigEntry “MEDI5752”, read by our name ru…›Nov 3 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundINT011066Entry “AZD7789”, read by our name rule›Nov 3 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackground

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Datopotamab deruxtecan

From the registry record3 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Datopotamab deruxtecan”the record gives no role
→judged→changed→changed
How the 3 judgments split33%of judgments with a known value say Tested
Tested · 1
Background · 2

All judgments on this study

WhenLinkJudgeDecisionState
Oct 27The record itselfClinicalTrials.gov recordVersion of 2026-10-27Record change
Nov 3Datopotamab deruxtecanClaude Opus 5.5BackgroundReplaced
Nov 3DurvalumabClaude Opus 5.5BackgroundCurrent
Nov 3CarboplatinClaude Opus 5.5TestedCurrent
Nov 3RilvegostomigClaude Opus 5.5BackgroundCurrent
Nov 3VolrustomigClaude Opus 5.5BackgroundCurrent
Nov 3INT011066Claude Opus 5.5BackgroundCurrent
Nov 3Datopotamab deruxtecanClaude Opus 5.5TestedCurrent
Nov 14Carcinoma, Non-Small-Cell LungRule based · condition-kind ruleFinest filed termCurrent
Nov 18Datopotamab deruxtecanRule based · role ruleBackgroundOverridden
Nov 18DurvalumabRule based · role ruleBackgroundAgrees
Nov 18CarboplatinRule based · role ruleTestedAgrees
Nov 18RilvegostomigRule based · role ruleBackgroundAgrees
Nov 18VolrustomigRule based · role ruleBackgroundAgrees
Nov 18INT011066Rule based · role ruleBackgroundAgrees
As of nowCarcinoma, Non-Small-Cell LungRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.